论文部分内容阅读
目的通过分析北京市朝阳医院肿瘤科住院病人在北京05版《药品目录》修订前后的用药变化情况,预测抗肿瘤药物的发展趋势,为临床用药提供依据。方法对2005年10月1日开始实施的北京05版《药品目录》前后一年中该院肿瘤科住院病人使用的抗肿瘤药物从销售金额、用药频度、日均费用的排序进行统计分析和比较。结果通过统计分析对比,修订前后一年中药品使用情况发生了较大的变化。修订后艾迪、乌苯美司、吉西他滨等的销售金额呈大幅度的上升态势;修订后乌苯美司、艾迪、华蟾素、卡培他滨等的用药频度上升;修订后的日均费用都较修订前有不同程度的降低。结论有更多临床必需、安全有效、价格合理的药品用于肿瘤患者,降低了患者使用目录外药品的比例,维护了患者合法权益,保障了患者基本医疗需求。
Objective To predict the development trend of anticancer drugs by analyzing the changes of the medication before and after the revision of “Drugs Catalog” of Beijing 05 version inpatient department of oncology in Beijing Chaoyang Hospital, and provide basis for clinical medication. Methods The antitumor drugs used in oncology inpatients of the hospital in Beijing 05 edition “Drug Catalog” which was put into effect on October 1, 2005 were statistically analyzed from the order of sales amount, frequency of medication and average daily cost Compare The results of statistical analysis of the comparison, the revision of the year before the use of drugs has undergone major changes. After the revision, the sales amount of Eddie, Ubenimex, Gemcitabine and so on increased significantly. The revised frequency of Ubenimex, Eddie, Cinobufotalin and Capecitabine increased. The revised Average daily expenses have been reduced to varying degrees compared with the previous revision. Conclusions There are more clinically necessary, safe and effective drugs with reasonable prices for cancer patients, reducing the proportion of patients using drugs outside the catalog, safeguarding the legitimate rights and interests of patients, and ensuring the basic medical needs of patients.